Information Provided By:
Fly News Breaks for January 17, 2020
ICPT
Jan 17, 2020 | 09:38 EDT
JMP Securities analyst Liisa Bayko noted that Intercept reported that the FDA has extended the PDUFA target action date to June 26 for the New Drug Application for obeticholic acid in liver fibrosis due to NASH, stating that the updated PDUFA date is consistent with her adjusted timelines after the FDA announced an advisory committee meeting was being called. Obeticholic acid remains the only drug to meet the primary endpoint of a Phase 3 NASH study to date, said Bayko, who continues to recommend Intercept shares and maintains her Outperform rating and $200 price target on the stock.
News For ICPT From the Last 2 Days
There are no results for your query ICPT